1. A compound having the structure I:
wherein X is a moiety selected from a group consisting of a \u2014O\u2014CyH2y+1, \u2014O\u2014Z, \u2014O\u2014CH2\u2014C(O)\u2014R\u2032, and NR\u2033R\u2032\u2033, and wherein
R\u2032 is an alkyl; and
each of R\u2033 and R\u2032\u2033 is independently selected from a group consisting of H, an alkyl, an alkenyl, an alkadienyl, a substituted alkyl, benzyl, a substituted benzyl comprising a substituent attached directly to the ring, and a 3-methylenepyridyl, or N, R\u2033 and R\u2032\u2033 taken together form a heterocycle selected from a group consisting of pyrrolidine, morpholine, and piperazine,
Z is alkenyl or alkadienyl,
y is selected from the group consisting of 2, 3, 5-10,
with the further proviso that in each of the \u2014O\u2014CyH2y+1, R\u2032, R\u2033 and R\u2032\u2033, the alkyl, the alkenyl, where present, is straight-chained or branched.
2. The compound of claim 1, wherein the compound is selected from a group consisting of compounds II-XV:
3. The compound of claim 2, wherein the compound is selected from a group consisting of compounds II, IV-VIII, and XII-XV.
4. The compound of claim 2, wherein the compound is selected from a group consisting of compounds XIII and XV.
5. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
What is claimed is:
1. A recombinant polypeptide of the following (a), (b) or (c):
(a) a polypeptide comprising an amino acid sequence shown in SEQ ID NO: 2;
(b) a polypeptide comprising an amino acid sequence having deletion, substitution or addition of at least one amino acid in the amino acid sequence shown in SEQ ID NO: 2, and having a high affinity binding activity to inositol 1,4,5-trisphosphate; or
(c) a polypeptide having at least 70% homology with the amino acid sequence shown in SEQ ID NO: 2, and having a high affinity binding activity with inositol 1,4,5-trisphosphate.
2. An antagonist for IP3-induced calcium comprising the protein of claim 1.
3. A therapeutic agent diseases associated with calcium production comprising the protein of claim 1.
4. An agent for gene therapy for diseases associated with calcium production comprising the gene of claims 2 or 3.
5. The therapeutic agent of claim 4, wherein the disease is at least one disease selected from the group consisting of diseases in the nervous system, blood vascular system, respiratory system, digestive system, lymphatic system, urinary system and reproduction system.